Revolution Medicines (RVMD) Net Cash Flow (2019 - 2026)

Revolution Medicines' Net Cash Flow history runs 8 years deep, the most recent figure standing at $57.2 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 127.3% year-over-year to $57.2 million; the TTM figure through Mar 2026 stood at $108.5 million (up 137.05% YoY), while the FY2025 annual figure was -$158.2 million, down 3.77% from the prior year.
• Net Cash Flow was $57.2 million for Q1 2026 at Revolution Medicines, down from $166.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $342.6 million in Q4 2024 to a low of -$407.7 million in Q1 2024.
• Historically, Net Cash Flow has averaged $19.7 million across 5 years, with a median of -$10.8 million in 2022.
• Biggest YoY gain for Net Cash Flow was 2554.39% in 2023; the steepest drop was 667.35% in 2023.
• A 5-year view of Net Cash Flow shows it stood at -$17.5 million in 2022, then jumped by 2030.45% to $338.4 million in 2023, then advanced by 1.25% to $342.6 million in 2024, then plunged by 51.46% to $166.3 million in 2025, then slumped by 65.61% to $57.2 million in 2026.
• The last three Net Cash Flow figures came in at $57.2 million (Q1 2026), $166.3 million (Q4 2025), and -$184.1 million (Q3 2025), per Business Quant data.